Searchable abstracts of presentations at key conferences in endocrinology

ea0099p90 | Endocrine-Related Cancer | ECE2024

Does mitotane offer lasting cure or transitory benefits following adrenocortical carcinoma surgery?

Escola Cristina Alvarez , Cubero Jorge Hernando , Mangas Cruz Miguel Angel , Donas Jesus Garcia , Cesar Maria Jose Picon , Fano Miguel Paja , Fernandez Laura Gonzalez , Batanero Lorena Gonzalez , Garcia-Garcia-Doncel Lourdes , Molina-Cerrillo Javier , Martinez Trufero Javier , Blanco Brenda Veiguela , Sanchez Beatriz Febrero , Hanzu Felicia A , Lopez Carlos , Blanco Concepcion , Ramon Y Cajal Teresa , Salas Jersy Jair Cardenas , Valdes Nuria , Fonseca Paula Jimenez , Bayonas Alberto Carmona

Introduction: The role of mitotane as an adjuvant therapy for adrenocortical carcinoma (ACC) remains a contentious topic due to the scarcity of robust randomized clinical trials, attributed to the low incidence of this neoplasm. Despite this, the prognosis following surgery for localized tumors is generally poor, leading to varied clinical practices.Methods: This study utilized patient data from the ICARO registry of the GETHY group and SEEN, with diseas...